AIP
RYTM icon

Ameritas Investment Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Ameritas Investment Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$556K Buy
5,010
+645
+15% +$58.3K 0.01% 863
2026
Q1 		$380K Hold
4,365
– – 0.01% 928
2025
Q4 		$467K Hold
4,365
– – 0.01% 843
2025
Q3 		$441K Sell
4,365
-1,181
-21% -$110K 0.01% 867
2025
Q2 		$350K Hold
5,546
– – 0.01% 987
2025
Q1 		$294K Hold
5,546
– – 0.01% 1058
2024
Q4 		$310K Hold
5,546
– – 0.01% 1066
2024
Q3 		$291K Buy
5,546
+228
+4% +$10.9K 0.01% 1103
2024
Q2 		$218K Hold
5,318
– – 0.01% 1207
2024
Q1 		$230K Hold
5,318
– – 0.01% 1193
2023
Q4 		$244K Buy
5,318
+251
+5% +$7.92K 0.01% 1141
2023
Q3 		$116K Buy
5,067
+825
+19% +$18.5K ﹤0.01% 1546
2023
Q2 		$70K Buy
+4,242
New +$76.6K ﹤0.01% 1832
2022
Q2 		– Sell
-3,454
Closed -$40K – 3212
2022
Q1 		$40K Hold
3,454
– – ﹤0.01% 2193
2021
Q4 		$34K Hold
3,454
– – ﹤0.01% 2376
2021
Q3 		$45K Hold
3,454
– – ﹤0.01% 2237
2021
Q2 		$68K Buy
3,454
+484
+16% +$10.1K ﹤0.01% 1977
2021
Q1 		$63K Hold
2,970
– – ﹤0.01% 1948
2020
Q4 		$88K Hold
2,970
– – ﹤0.01% 1646
2020
Q3 		$64K Hold
2,970
– – ﹤0.01% 1687
2020
Q2 		$66K Buy
2,970
+455
+18% +$8.87K ﹤0.01% 1672
2020
Q1 		$38K Hold
2,515
– – ﹤0.01% 1820
2019
Q4 		$58K Buy
2,515
+529
+27% +$11.8K ﹤0.01% 1836
2019
Q3 		$43K Hold
1,986
– – ﹤0.01% 1978
2019
Q2 		$44K Buy
1,986
+970
+95% +$24.5K ﹤0.01% 1990
2019
Q1 		$28K Hold
1,016
– – ﹤0.01% 2205
2018
Q4 		$27K Hold
1,016
– – ﹤0.01% 2164
2018
Q3 		$30K Hold
1,016
– – ﹤0.01% 2291
2018
Q2 		$32K Buy
1,016
+316
+45% +$8.64K ﹤0.01% 2250
2018
Q1 		$14K Hold
700
– – ﹤0.01% 2601
2017
Q4 		$20K Buy
+700
New +$18.5K ﹤0.01% 2438

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ameritas Investment Partners's RYTM Position: Q2 2026 in Review

Ameritas Investment Partners increased its Rhythm Pharmaceuticals (RYTM) stake by 15% in Q2 2026, buying an estimated $58.3K and bringing the position to 5,010 shares worth $556K. The position accounts for 0.01% of the portfolio, ranked #863.

Ameritas Investment Partners first reported a position in RYTM in Q4 2017 and has held it in 31 quarters since. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Ameritas Investment Partners held 5,010 shares of Rhythm Pharmaceuticals worth $556K as of Q2 2026.
  • Ameritas Investment Partners bought 645 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $58.3K.
  • Rhythm Pharmaceuticals made up 0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #863 holding.
  • Ameritas Investment Partners first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 31 quarters since.
  • 302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.